Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Invitrogen Develops new Technology to Promote Safer Stem Cell Therapies

Published: Thursday, May 14, 2009
Last Updated: Thursday, May 14, 2009
Bookmark and Share
Dynabeads’ solution separates undifferentiated stem cells from differentiated cells to support translational research.

Invitrogen, a division of Life Technologies, has announced a new technology to enable the development of safer stem cell therapies. Dynabeads’ SSEA-4 addresses a key challenge in translational research, by separating undifferentiated stem cells from those that are differentiated.

Scientists from Invitrogen and the Buck Institute for Age Research, located in Novato, California, collaborated in developing this solution that depletes greater than 99 % of undifferentiated human embryonic stem cells from differentiated populations. They are presenting data on this new technology at the International Society for Cellular Therapy Meeting in San Diego.

Human embryonic stem cell research is one of the fastest growing areas in cell biology. These cells have unlimited proliferative capacity and can differentiate into multiple types, providing an infinite resource for many potential translational medicine applications.

A key issue for translational stem cell researchers is the ability to reliably identify and isolate undifferentiated hESCs, which are not considered as suitable for transplantation as those which are differentiated, because of the potential of unregulated cell growth. Their objective is to obtain pure and homogenous cell populations, which will help to ensure the safe development and manufacturing of therapeutics.

Dynabeads SSEA-4 achieves this by utilizing magnetic beads that latch onto a common marker on embryonic and induced pluripotent stem cells, removing them from a culture in less than 45 minutes. This leaves behind highly pure and differentiated cells that are unaffected by the Process.

Paul Pickering, General Manager of Invitrogen Cell Therapy Systems Business at Life Technologies said, “Dynabeads SSEA-4 is an innovative and highly effective solution that addresses one of the key challenges in the development of safer stem cell therapies. It was made possible through the collaboration of several technologies and business groups from different parts of the company coming together to offer a single solution to a problem faced by many of our stem cell customers.”

Xianmin Zeng, Ph.D., Associate Professor, Buck Institute, “Using Dynabeads SSEA-4, we are able to deplete greater than 99% of pluripotent cells in neural cell populations derived from pluripotent cells, which are likely targets for transplant therapy for neurodegenerative disorders.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Invitrogen Awarded $970K Contract by U.S. Department of Defense
Invitrogen has been awarded to produce and validate protein microarrays to biothreat agents.
Friday, January 13, 2006
Scientific News
Diagnostic Thread - Weaving the Future?
Researchers have created diagnostic threads that could pave the way for next-gen implantable and wearable diagnostics.
R&D Agreement for Development of CtDNA Diagnostics
SeraCare and NIST partner for development of ctDNA diagnostic assay reference materials.
Adipose Analysis on Microfluidic Chips
Scientists have developed a microfluidic chip the works with minute liquid quantities to grow and study cells.
New Device can Study Electric Field Cancer Therapy
Microfluidic device allows study of electric field cancer therapy through low-intensity fields, preventing malignant cells spreading.
DNA Production Facility Begins Operation
Scientists mark the opening of the UK's first fully automated DNA construction and modification facility.
A “Micro Winery” That Makes Wine Continuously
An American professor, working in collaboration with EPFL, is developing a miniature device for producing wine non-stop and testing different fermentation processes.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
Tough New Hydrogel Hybrid Doesn’t Dry Out
Water-based material could be used to make artificial skin, longer-lasting contact lenses.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
A Future Tool for Medicine, Food Safety
A new type of electronic sensor that might be used to quickly detect and classify bacteria for medical diagnostics and food safety has passed a key hurdle by distinguishing between dead and living bacteria cells.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!